MoneyInvestor's Business Daily
Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded
Climb Bio reversed course Thursday despite potential "best-in-class" data for its experimental kidney disease treatment. The post Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded appeared first on Investor's Business Daily.
Join the argument
House rules →Comments load as you scroll.